Faculty

Main navigation

MEG@McGill Comprehensive Training (Second Edition)

Monday, November 16, 2015toFriday, November 20, 2015

It is with great pleasure that we are announcing the 2nd edition of the MEG@McGill Comprehensive Training Program in 2015.3801 rue University, Montreal, QC, H3A 2B4, CA/bicCategory: MNI

Read more about MEG@McGill Comprehensive Training (Second Edition)

AI analysis of healthcare records reveals key factors in autism diagnosis

Published: 26 March 2025

Scientists argue the criteria we use for diagnosing autism may need revision...

Read more about AI analysis of healthcare records reveals key factors in autism diagnosis

Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

Published: 14 March 2025

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation...

Read more about Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

Project to create AI model for ALS receives Génome Québec funding

Published: 17 March 2025

$400,000 will fuel public-private collaboration to discover new disease biomarkers...

Read more about Project to create AI model for ALS receives Génome Québec funding

Genetic sequencing project receives more than $8 million in funding

Published: 18 March 2025

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians...

Read more about Genetic sequencing project receives more than $8 million in funding

Six principal investigators from The Neuro receive CIHR grants

Published: 10 February 2025

Projects include important research on Parkinson’s, glioblastoma and dementia

Read more about Six principal investigators from The Neuro receive CIHR grants

Latest Alzheimer’s drug shown less effective in females than males

Published: 18 March 2025

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...